Endocrine therapy in pancreatic carcinoma

Oncology

Volumn 55, Issue SUPPL. 1, 1998, Pages 17-21

  Yamashita, Jun Ichi ^a   Abe, Michio ^a   Ogawa, Michio ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Endocrine therapy; Estrogen dependence; Medroxyprogesterone acetate; Pancreatic carcinoma; Tissue plasminogen activator

Indexed keywords

AROMATASE INHIBITOR; ESTROGEN RECEPTOR; GONADORELIN DERIVATIVE; MEDROXYPROGESTERONE ACETATE; TAMOXIFEN; TISSUE PLASMINOGEN ACTIVATOR; TOREMIFENE;

CANCER HORMONE THERAPY; CLINICAL TRIAL; CONFERENCE PAPER; HORMONE DEPENDENCE; HUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROGNOSIS;

ANTINEOPLASTIC AGENTS, HORMONAL; ESTROGEN ANTAGONISTS; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; NEOPLASMS, HORMONE-DEPENDENT; PANCREATIC NEOPLASMS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0032424080     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000055255     Document Type: Conference Paper

References (52)

1. Pancreatic Cancer Registration Committee of Japan Pancreatic Society: Annual Report of National Registration of Pancreatic Cancer Patients in 1985. Kobe, Japan Pancreatic Society, 1986, pp 38-44.
2. Zimmerman SE, Smith FP, Schein PS: Chemotherapy of pancreatic carcinoma. Cancer 1981; 47:1724-1728.
3. Moertel CG, Frytak S, Hahn RG, O'Connell MJ, Reitemier RJ, Rubin J, Schutt AJ, Weiland LH, Childs DS, Holbrook MA, Lavin PT, Livstone E, Spiro H, Knowlton A, Kalser M, Barkin J, Lessner H : Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil. Cancer 1981;48:1705-1710.
4. Cullinan S, Moertel CG, Wieand HS, Schutt AJ, Krook JE, Foley JF, Norris BD, Kardinal CG, Tschetter LK, Barlow JF: A phase III trial on the therapy of advanced pancreatic carcinoma. Cancer 1990;65:2207-2212.
5. Greenway B, Igbal MJ, Johnson PJ, Williams R: Oestrogen receptor protein in malignant and fetal pancreas. Br Med J 1981;283:751-753.
6. Andren-Sanderg A, Borg S, Dawiskiba I, Ferno M: Estrogen receptors and estrogen binding protein in pancreatic cancer. Digestion 1982;25: 12-13.
7. Benz C, Hollander C, Miller B: Endocrine responsive pancreatic carcinoma steroid binding and cytotoxic studies in human tumor cell lines. Cancer Res 1986;46:2276-2281.
8. Theve NO, Pousette A, Carlström K: Adenocarcinoma of the pancreas - A hormone sensitive tumor? A preliminary report on Nolvadex treatment. Clin Oncol 1983;9:193-197.
9. Tonnesen K, Kamp-Jensen M: Antiestrogen therapy in pancreatic carcinoma: A preliminary report. Eur J Surg Oncol 1986;12:69-70.
10. Crowson MC, Dorrell A, Rolfe EB, Fielding JWL: A phase II study to evaluate tamoxifen in pancreatic adenocarcinoma. Eur J Surg Oncol 1986;12:335-336.
11. Wong A, Chan A, Arthur K: Tamoxifen therapy in unresectable adenocarcinoma of the pancreas. Cancer Treat Rep 1987;71:749-750.
12. Keating JJ, Johnson PJ, Cochrane AMG, Gazzard BG, Krasner N, Smith PM, Trewby PN, Wheeler P, Wilkinson SP, Williams R: A prospective randomised controlled trial of tamoxifen and cyproterone acetate in pancreatic carcinoma. Br J Cancer 1989;60:789-792.
13. Scheithauser W, Kornek G, Haider K, Depisch D: Unresponsiveness of pancreatic adenocarcinoma to antiestrogen therapy. Eur J Cancer 1990;26:773-775.
14. Bakkevold KE, Pettersen A, Arnesjo B, Espehaug B: Tamoxifen therapy in unresectable adenocarcinoma of the pancreas and the papilla of Vater. Br J Surg 1990;77:725-730.
15. Wong A, Chan A: Survival benefit of tamoxifen therapy in adenocarcinoma of pancreas. Cancer 1993;71:2200-2203.
16. McGuire WL: Endocrine therapy of breast cancer. Annu Rev Med 1975;26:353-363.
17. Butler WB, Kirkland WL, Jorgensen TL: Induction of plasminogen activator by estrogen in a human breast cancer cell line (MCF-7). Biochem Biophys Res Commun 1979;90:1328-1334.
18. Butler WB, Kirkland WL, Gargala TL, Goran N, Kelsey WH, Berlinski PJ: Steroid stimulation of plasminogen activator production in a human breast cancer cell line (MCF-7). Cancer Res 1983;43:1637-1641.
19. Ryan TJ, Seeger JI, Kumar AA, Dickermann HW: Estradiol preferentially enhances extracellular tissue plasminogen activators of MCF-7 breast cancer cells. J Biol Chem 1984;259: 14324-14327.
20. Yamashita J, Horiuchi S, Shigaki N, Fujino N, Akagi M: Estrogen-dependent plasminogen activator in 7,12-dimethylbenz[a]anthracene-induced rat mammary tumors in vivo and in vitro. Jpn J Cancer Res 1984;75:681-689.
21. Inada K, Yamashita J, Yoshimura T, Matsuo S, Nakashima Y, Yamashita S, Misumi A, Ogawa M: Hormonal regulation of plasminogen activator and peroxidase in 7,12-dimethylbenz-[a]anthracene (DMBA)-induced rat mammary tumors and the rat uterus. Jpn J Surg 1991;21: 249-252.
22. Yamashita J, Inada K, Yamashita S, Matsuo S, Nakashima Y, Ogawa M: Specific stimulation by estradiol of tissue-type plasminogen activator production in 7,12-dimethylbenz[a]anthracene-induced rat mammary tumor cells. Horm Metab Res 1992;24:565-569.
23. Inada K, Yamashita J, Matsuo S, Nakashima S, Yamashita S, Ogawa M: Hormone control of total plasminogen activator activity is specific to malignant DMBA-induced rat mammary tumours. Br J Cancer 1992;65:578-582.
24. Yamashita J, Horiuchi S, Kimura M, Nishimura R, Akagi M: Plasminogen activator as a functional marker for estrogen dependence in human breast cancer cells. Jpn J Cancer Res 1986;77: 177-181.
25. Mira-Y-Lopez R, Osborne MP, Depalo AJ, Ossowski L: Estradiol modulation of plasminogen activator production in organ cultures of human breast carcinomas: Correlation with clinical outcome of antiestrogen therapy. Int J Cancer 1991;47:827-832.
26. Rella C, Coviello M, Quaranta M, Angelo P: Tissue-type plasminogen activator as marker of functional steroid receptors in human breast cancer. Thromb Res 1993;69:209-220.
27. Yamashita J, Ogawa M, Yamashita S, Nakashima Y, Saishoji T, Nomura K, Inada K, Kawano I: Differential biological significance of tissue-type and urokinase-type plasminogen activator in human breast cancer. Br J Cancer 1993;68:524-529.
28. Kuramoto M, Yamashita J, Ogawa M: Tissue-type plasminogen activator predicts endocrine responsiveness of human pancreatic carcinoma cells. Cancer 1995;75:1263-1272.
29. Kangas L: Review of the pharmacological properties of toremifene. J Steroid Biochem 1990; 36:191-195.
30. Crighton IL, Dowsett M, Lal A, Man A, Smith IE: Use of luteinising hormone-releasing hormone agonist (leuprorelin) in advanced postmenipausal breast cancer: Clinical and endocrine effects. Br J Cancer 1989;60:644-648.
31. Furr BJA, Nicholson RI: Use of analogues of luteinizing hormone-releasing hormone for the treatment of cancer. J Reprod Fert 1982;64:529-539.
32. Bhatnagar AS, Hausler A, Schieweck K, Lang M, Bowman R: Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor. J Steroid Biochem Mol Biol 1990;37:1021-1027.
33. Anderson DG: Management of advanced endometrial adenocarcinoma with medroxyprogesterone acetate. Am J Obstet Gynecol 1965;92: 87-99.
34. Pannuti F, Di Marco AR, Martoni A: Medroxyprogesterone acetate in the treatment of metastatic breast cancer. Seven years of experience; in Iacobelli S, Di Marco A (eds): Role of Medroxyprogesterone in Endocrine-Related Tumors: Progress in Cancer Research and Therapy. New York, Raven Press, 1980, vol 15, pp 73-92.
35. Hsueh AJW, Peck JEJ, Clark JH: Progesterone antagonism of the oestrogen receptor and oestrogen-induced uterine growth. Nature (Lond) 1975;254:337-339.
36. Carlo FD, Conti G, Reboani C: Interference of gestagens and androgens with rat uterine oestrogen receptors. J Endocrinol 1978;77:49-55.
37. Sala G, Castegnaro E, Lenaz GR, Martoni A, Pianna E, Pannuti F: Hormone interference in metastatic breast cancer patients treated with medroxyprogesterone acetate at massive doses: Preliminary results. IRCS Med Sci 1978;6:129-130.
38. Hellman L, Yoshida K, Zumoff B, Levin J, Kream J, Fukushima DK: The effect of medroxyprogesterone acetate on the pituitary-adrenal axis. J Clin Endocrinol Metab 1976;42: 912-917.
39. Danguy A, Legros N, Devleeschouwer N, Heuson-Stennon JA, Heuson JC: Effects of medroxyprogesterone acetate (MPA) on growth of DMBA-induced rat mammary tumors: Histopathologic and endocrine studies; in Iacobelli S, Di Marco A (eds): Role of Medroxyprogesterone in Endocrine-Related Tumors: Progress in Cancer Research and Therapy. New York, Raven Press, 1980, vol 15, pp 21-28.
40. Blossey HC, Wander HE, Koebberling J, Nagel GA: Pharmacokinetic and pharmacodynamic basis for the treatment of metastatic breast cancer with high-dose medroxyprogesterone acetate. Cancer 1984;54:1208-1215.
41. Gregory EJ, Cohen SC, Oines DW, Mims CH: Megestrol acetate therapy for advanced breast cancer. J Clin Oncol 1985;3:155-160.
42. Benghiat A, Cassidy SA, Davidson HE, Mancero FS, Pickard JG, Tyrrell CJ: Megestrol acetate in the treatment of advanced postmenopausal breast cancer. Eur J Surg Oncol 1986; 12:43-45.
43. Morgan LR: Megestrol acetate vs tamoxifen in advanced breast cancer in postmenopausal patients. Semin Oncol 1985;12:43-47.
44. Tchekmedyian NS, Tait N, Moody M, Greco FA, Ansner J: Appetite stimulation with megestrol acetate in cachectic cancer patients. Semin Oncol 1986;13:37-43.
45. Creagan ET, Ingle JN, Schutt AJ, Schaid DJ: A prospective, randomized controlled trial of megestrol acetate among high-risk patients with resected malignant melanoma. Am J Clin Oncol 1989;12:152-155.
46. Bonomi P, Pessis D, Bunting N, Block M, Anderson K, Wolter J, Rossof A, Slayton R, Harris J: Megestrol acetate used as primary hormonal therapy in stage D prostatic cancer. Semin Oncol 1985;12:36-39.
47. Sedlacek SM: An overview of megestrol acetate for the treatment of advanced breast cancer. Semin Oncol 1988;15:3-13.
48. Loprinzi CL, Ellison NM, Schaid DJ, Krook JE, Athmann LM, Dose AM, Mailliard JA, Johnson PS, Ebbert LP, Geeraerts LH: Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J Natl Cancer Inst 1990;82:1127-1132.
49. Von Roenn JH, Murphy RL, Weber KM, Williams LM, Weitzman SA: Megestrol acetate for treatment of cachexia associated with human immunodeficiency virus (HIV) infection. Ann Intern Med 1988;109:840-841.
50. Strassmann G, Fong M, Kenney J, Jacob CO: Evidence for the involvement of interleukin-6 in experimental cancer cachexia. J Clin Invest 1992;89:1681-1684.
51. Ohe Y, Podack ER, Olsen KJ, Miyahara Y, Miura K, Saito H, Koishihara Y, Ohsugi Y, Ohira T, Nishio K, Saijo N: Interleukin-6 cDNA transfected Lewis lung carcinoma cells show unaltered net tumour growth rate but cause weight loss and shorten survival in syngeneic mice. Br J Cancer 1993;67:939-944.
52. Yamashita J, Hideshima T, Shirakusa T, Ogawa M: Medroxyprogesterone acetate treatment reduces serum interleukin 6 levels in patients with metastatic breast cancer. Cancer 1996;78:2346-2352.